The FDA-approved compound, pramipexole and the clinical-stage investigational drug, dexpramipexole, reverse chronic allodynia from sciatic nerve damage in mice, and alter IL-1β and IL-10 expression from immune cell culture
Titel:
The FDA-approved compound, pramipexole and the clinical-stage investigational drug, dexpramipexole, reverse chronic allodynia from sciatic nerve damage in mice, and alter IL-1β and IL-10 expression from immune cell culture
Auteur:
Sanchez, J.E. Noor, S. Sun, M.S. Zimmerly, J. Pasmay, A. Sanchez, J.J. Vanderwall, A.G. Haynes, M.K. Sklar, L.A. Escalona, P.R. Milligan, E.D.